C3435T mutation in exon 26 of the human MDR1 gene and cyclosporine pharmacokinetics in healthy subjects

被引:67
作者
Min, DI [1 ]
Ellingrod, VL [1 ]
机构
[1] Univ Iowa, Coll Pharm, Div Clin & Adm Pharm, Iowa City, IA 52242 USA
关键词
MDR1 gene mutation; P-glycoprotein; cyclosporine; pharmacokinetics;
D O I
10.1097/00007691-200206000-00012
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
To determine the relationship between C3435T mutation in exon 26 of the human multidrug resistant 1 (MDR1) gene and cyclosporine pharmacokinetic parameters among healthy volunteers, the oral cyclosporine pharmacokinetic study was performed for 14 healthy subjects, Blood cyclosporine concentrations were measured by HPLC. Concentration-time data were analyzed by a noncompartmental method using WinNonLin, and the blood samples were genotyped for the C3435T polymorphism of MDR1 gene using the PCR and a restriction digest. Each cyclosporine pharmacokinetic parameter was compared using the Mann-Whitney U test according to his or her P-gp genotype. There were seven (7) homozygous Cl, six (6) C/T, and one (1) homozygous T/T genotypes in these 14 healthy volunteers. According to their genotypes, mean t(max) 1.6+/-0.3 hours, mean C-max 1337+/-329 ng/mL, mean Cl/F 66.5+/-18.3 L/h, and mean AUC 5642+/-1577 ng.h/mL in C1/F group and mean t(max) 2.0+/-0.6 hours, mean C-max 1540+/-721 ng/mL, mean Cl/F 55.2+/-18.9 L/h, and mean AUC 6902+/-1405 ng.h/mL in C/T+T/T group. Although C-max and AUC in C/T and T/T group were 15% and 227c larger than those in C/C group, none of these parameter comparisons was statistically significant. There were no statistical differences in cyclosporine pharmacokinetics among different MDR1 genotypes in these 14 healthy subjects.
引用
收藏
页码:400 / 404
页数:5
相关论文
共 25 条
  • [11] DEMOGRAPHIC-FACTORS INFLUENCING CYCLOSPORINE PHARMACOKINETIC PARAMETERS IN PATIENTS WITH UREMIA - RACIAL-DIFFERENCES IN BIOAVAILABILITY
    LINDHOLM, A
    WELSH, M
    ALTON, C
    KAHAN, BD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (04) : 359 - 371
  • [12] FACTORS INFLUENCING THE PHARMACOKINETICS OF CYCLOSPORINE IN MAN
    LINDHOLM, A
    [J]. THERAPEUTIC DRUG MONITORING, 1991, 13 (06) : 465 - 477
  • [13] P-glycoprotein and drug therapy in organ transplantation
    Lo, A
    Burckart, GJ
    [J]. JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (10) : 995 - 1005
  • [14] Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
    Lown, KS
    Mayo, RR
    Leichtman, AB
    Hsiao, HL
    Turgeon, DK
    SchmiedlinRen, P
    Brown, MB
    Guo, WS
    Rossi, SJ
    Benet, LZ
    Watkins, PB
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 62 (03) : 248 - 260
  • [15] Effect of intestinal P-glycoprotein on daily tacrolimus trough level in a living-donor small bowel recipient
    Masuda, S
    Uemoto, S
    Hashida, T
    Inomata, Y
    Tanaka, K
    Inui, K
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (01) : 98 - +
  • [16] Gender-dependent racial difference in disposition of cyclosporine among healthy African American and white volunteers
    Min, DI
    Lee, M
    Ru, YM
    Flanigan, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2000, 68 (05) : 478 - 486
  • [17] Nauck M, 2000, CLIN CHEM, V46, P1995
  • [18] SAWCHUK RJ, 1981, CLIN CHEM, V27, P1368
  • [19] Schinkel AH, 1998, INT J CLIN PHARM TH, V36, P9
  • [20] Schuetz EG, 2000, MOL PHARMACOL, V57, P188